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Initiate universal voluntary ART 
regardless of CD4 cell counts and 
within 10 years South Africa’s HIV 
incidence and mortality will drop to less 
than 1 case per 1 000 people per year 
and within 50 years prevalence will be 
reduced to below 1%.
With other prevention methods 
hardly impacting on the epidemic, 
the lowering of the amount of HIV in 
infected people through ARV drugs 
is the most effective way of reducing 
new infections, five World Health 
Organization (WHO) researchers argue 
in a provocative article published in 
The Lancet last November.1 According 
to their model, each untreated infected 
person infects 7 others before dying, 
fuelling and prolonging the pandemic. 
Continuing treating as we are would 
cost as much over the long run as 
introducing testing and universal 
treatment on an unprecedented scale.
The cogently reasoned and sensitive 
mathematical model is based on 
South African epidemiological data. 
It streamlines Canadian research 
published 2 years ago, derided and 
dismissed on grounds of expense, 
toxicity and drug resistance, factors that 
today carry less weight, enabling the 
vital debate to finally take off.
Co-author of the study, WHO HIV/
AIDS Director Kevin De Cock, says 
the idea is ‘to stimulate discussion’. 
A central pillar of the model is the 
widely held assumption that treatment 
reduces a person’s infectivity by 99%. 
Comparisons are made of the impact 
of thwarting new infections when 
people start treatment at various stages 
of immune decline. The model also 
assumes that all adults in test case 
communities accept being tested for 
HIV once a year on average and that 
all HIV-infected people access ARVs as 
soon as they are diagnosed positive.
SA the research guinea pig
Citing South Africa’s adult prevalence 
of 17% and using a higher cut-off 
treatment initiation CD4+ count of 350 
than the current 200 level (which the 
South African National AIDS Council 
(SANAC) is considering upping), 
the study estimates that at this point 
an HIV-positive person has already 
infected three others. However, if 
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treatment started shortly after people 
became infected, the HIV-positive 
person would on average infect less 
than 1 person each, and the severe 
South African epidemic would die out 
in 14 years. The strategy could also 
help reduce the incidence of TB and the 
transmission of HIV from mother to 
child.
De Kock counters the argument that 
poor countries can only afford to treat 
those most in need (200 CD4s and 
below) by noting that 3 million citizens 
of such countries now receive ARVs 
that were once deemed impossibly 
expensive for them.
The new model on the block brings 
into sharp focus the debate over public 
health versus individual benefits. It 
comes hot on the heels of appeals for 
researchers to apply their findings for 
the common good instead of ‘hiding 
behind the fig-leaf of individual 
rights’, made in an ethics session at the 
Global Ministerial Forum on Research 
for Health in Bamako, Mali in mid-
November last year.
Geoffrey Garnett, an epidemiologist 
at Imperial College London (St Mary’s), 
says the model promotes public health 
over individual benefits. He adds that 
it remains unclear that early treatment 
delays disease and death and could 
actually increase the risk of drug 
resistance developing.
Quoted on Science Mag.Org, Garnett 
contends that eliminating the epidemic 
is too ambitious a goal given the ethical, 
financial and logistical issues. However, 
he notably concedes that even if the 
strategy didn’t reach all infected people, 
it ‘could have a big impact on spread’. 
‘It’s not an idea to dismiss out of hand 
– it really throws down the gauntlet,’ 
he says.
Detractors of the theory cite the 80% 
of infected people in sub-Saharan Africa 
who do not know their status, the 
toxicity and resistance dangers of sub-
standard ARVs (so often used in poorer 
countries), compliance and start-up and 
maintenance costs.
Spend billions now, save money 
and lives tomorrow
The WHO researchers’ preliminary cost 
analysis for South Africa shows that by 
2015 the country would have to spend 
three times as much on testing and 
treatment as it does today – but because 
of declining infection rates, costs would 
then begin to steadily decline.
Says De Kock: ‘In the long run 
it saves money. Front loading the 
investment on ARVs is a very wise 
choice, even in a time of financial crisis.’ 
He concedes that more research is 
needed to prove that starting treatment 
at the earliest possible point does not 
lead to toxicities and drug resistance 
that offset long-term benefits.
Bringing it down to basics, he asks: 
‘How would you like it if I say, “You 
don’t qualify for treatment, but I want 
to treat you so you don’t expose anyone 
else?”’ He and his team want research 
colleagues to conduct small-scale trials 
of voluntary testing and immediate 
treatment to assess the impact on 
infected individuals and see whether 
implementation bears out their sizzling 
theory.
An estimated 5.7 million South 
Africans were HIV positive last year 
(2008) when the epidemic had matured 
in five provinces but was still growing 
rapidly in the Eastern Cape and to 
a lesser extent in the Western Cape, 
Northern Cape and Limpopo.2 ‘Mature’ 
means that new infections and deaths 
are more or less at the same level so 
the total number of infected people 
remains constant. This overall national 
‘maturity’ has HIV infection and deaths 
converging to a level between 400 000 
and 500 000 per annum.
The largest number of HIV-positive 
people (1.5 million) live in KwaZulu-
Natal, where ART uptake is estimated 
at 43%. Gauteng has the second largest 
epidemic (1.4 million) with 60% of those 
in need of treatment having taken it up. 
The Eastern Cape lies third (730 000) 
with 44% ART uptake. The Western 
Cape has the highest ART take-up rate 
at 74%.
Local response cautiously 
optimistic
Most top South African HIV/AIDS 
actuaries agree that prevention 
strategies need dramatic upscaling 
while increased treatment take-up in 
provinces with mature epidemics will 
limit the impact of AIDS-related deaths 
on households and economies.
The Treatment Action Campaign 
(TAC) says mathematical and scientific 
communities need time to digest the 
new research before repeating it for 
vital confirmation. Rich countries 
would have to fund poor countries, if 
there was confirmation that led to pilot 
studies, the scale of which was open for 
debate.
The impact on adherence, 
acceptability and sexual behaviour 
needed ‘urgent probing’ while care was 
needed not to undermine any effective 
current prevention strategies.
‘If we answer these questions while 
vigorously pursuing current scaling up 
and the study’s recommendations are 
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feasible, Africa and the world would 
have a very different future,’ the TAC 
added.
Professor Helen Schneider of the 
University of the Witwatersrand’s 
Centre for Health Policy, was quoted 
as saying the model would require 
‘massive societal buy-in to get people 
tested once a year and to take treatment 
for public health purposes rather than 
individual benefit’. She questioned 
whether similar outcomes were not 
possible ‘if the same kind of effort,’ was 
invested in current programmes.
Izindaba sources within National 
Treasury said that the proposal would 
be ‘seriously considered from an 
economic perspective’– if the experts 
took a position that it was the most 
appropriate treatment modality backed 
by hard evidence. ‘But I think it would 
be limited far more by human resources 
and management capacity than by 
money,’ one observed.
Professor Salim Abdool Karim, 
Director of the Centre for the Durban-
based AIDS Programme of Research 
of South Africa (Caprisa), said the 
premise of the strategy remained 
theoretical until data emerged from 
the current HPTN 052 trial probing 
whether treating HIV-infected patients 
immediately after diagnosis reduces the 
likelihood of HIV transmission to their 
sero-discordant partners.
He believed South Africa’s 
overburdened health care system would 
be unlikely to cope with such rapid 
scale-up of testing and treatment, while 
drug toxicities, resistance and treatment 
adherence would pose substantial 
implementation challenges.
Within weeks, the WHO is due to 
bring together ethicists, funders, human 
rights advocates, clinicians, prevention 
experts and AIDS programme managers 
to discuss the research and other issues 
related to the wider use of ART.
The WHO stressed that male 
circumcision, partner reduction, 
correct and consistent use of condoms 
and interventions targeting most-at-
risk populations needed stringent 
maintenance and urgent expansion.
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